



February 7, 2014

## **Supernus at Citibank and RBC Global Healthcare Conferences in February**

ROCKVILLE, Md.--(BUSINESS WIRE)-- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company's management will be hosting investor meetings during Citi's 2014 Global Healthcare Conference.

Date: Tuesday, February 25  
Place: The Hilton New York Hotel

Investors interested in arranging a meeting during this conference should contact their Citi representative.

Supernus also announced that management will provide a business update on the Company at the 2014 RBC Capital Markets Global Healthcare Conference.

Date: Wednesday, February 26  
Presentation Time: 9:00am ET  
Place: The New York Palace, New York, NY

### **About Supernus Pharmaceuticals, Inc.**

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Supernus Pharmaceuticals, Inc.  
Jack A. Khattar, President and CEO  
Gregory S. Patrick, Vice President and CFO  
301-838-2591  
or  
Investor Contact:  
Cockrell Group  
877-889-1972  
[investorrelations@thecockrellgroup.com](mailto:investorrelations@thecockrellgroup.com)  
[cockrellgroup.com](http://cockrellgroup.com)

Source: Supernus Pharmaceuticals, Inc.

News Provided by Acquire Media